A Randomized, Controlled Clinical Trial of a Dermocosmetic Containing Vichy Volcanic Mineralizing Water and Probiotic Fractions in Subjects with Rosacea Associated with Erythema and Sensitive Skin and Wearing Protective Masks.

erythema exposome rosacea sensitive skin skin barrier

Journal

Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449

Informations de publication

Date de publication:
2023
Historique:
received: 30 09 2022
accepted: 05 01 2023
entrez: 20 1 2023
pubmed: 21 1 2023
medline: 21 1 2023
Statut: epublish

Résumé

Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces skin defences against exposome factors. This study assessed the benefit of M89PF in subjects with rosacea associated with erythema and sensitive skin during the Covid-19 pandemic using protective face masks. M89PF was compared to usual skin care in a randomized, split-face study, for 30 days in subjects with rosacea associated with erythema and sensitive skin. Clinical evaluations included erythema, desquamation, skin tightness, dryness, burning sensation, itching, stinging, stinging test, and local tolerability. Instrument evaluations included erythema, skin hydration and TEWL. Subject satisfaction was also assessed. Erythema significantly improved with M89PF at both time points (p<0.01 at D15, and p<0.001 at D30). Skin sensitivity assessed by the skin stinging test improved significantly (p<0.01) with M89PF at D30, compared to baseline and usual skin care. Skin erythema, tightness, dryness, hydration and TEWL significantly improved (p≤0.05) with M89PF at D15 and D30, versus baseline and the untreated side. Subjects were highly satisfied with M89PF at D15 and D30. Tolerance was very good in all subjects. In subjects with rosacea, M89PF significantly reduces erythema, skin tightness, dryness and TEWL, and improves skin hydration and skin sensitivity, even when using protective masks. M89PF is well tolerated and received high satisfaction ratings. NCT05562661.

Identifiants

pubmed: 36660190
doi: 10.2147/CCID.S391893
pii: 391893
pmc: PMC9843703
doi:

Banques de données

ClinicalTrials.gov
['NCT05562661']

Types de publication

Case Reports Clinical Trial

Langues

eng

Pagination

71-77

Informations de copyright

© 2023 Berardesca et al.

Déclaration de conflit d'intérêts

Adriana Bonfigli and Claudia Cartigliani are affiliated with ISPE. Delphine Kerob is an employee of Cosmetic Active International, France (a L’Oreal company). Jerry Tan is an advisor, consultant and speaker for Cosmetic Active International, France (a L’Oreal company). He also reports personal fees from Vichy, during the conduct of the study; personal fees from La Roche Posay, Vichy, and Galderma, outside the submitted work. The authors report no other conflicts of interest in this work.

Références

Dermatology. 2004;209(3):173-4
pubmed: 15459527
Arch Dermatol Res. 2018 Mar;310(2):139-146
pubmed: 29330632
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 2:26-34
pubmed: 34979590
J Cosmet Dermatol. 2019 Jun;18(3):815-820
pubmed: 30964240
Dermatol Clin. 2018 Apr;36(2):171-174
pubmed: 29499801
Front Physiol. 2014 Sep 29;5:352
pubmed: 25324778
J Drugs Dermatol. 2021 Apr 1;20(4):384-392
pubmed: 33852244
Exp Dermatol. 2020 Jan;29(1):15-21
pubmed: 31494971
Nat Rev Immunol. 2010 Mar;10(3):210-5
pubmed: 20168318
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 2:5-15
pubmed: 34979589
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 2:16-25
pubmed: 34979591
Allergy. 2020 Jan;75(1):63-74
pubmed: 31194890
J Am Acad Dermatol. 2018 Jan;78(1):156-166
pubmed: 29089181
Cells. 2020 Jul 21;9(7):
pubmed: 32708202
Dermatol Surg. 2005 Jul;31(7 Pt 2):860-5; discussion 865
pubmed: 16029679
Przegl Lek. 2008;65(9):371-4
pubmed: 19140384
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):163-168
pubmed: 27323701
Exp Dermatol. 2012 Dec;21(12):906-10
pubmed: 23171449
J Eur Acad Dermatol Venereol. 2022 Jan;36 Suppl 2:3-4
pubmed: 34979588
J Eur Acad Dermatol Venereol. 2018 May;32(5):812-819
pubmed: 29377341
J Am Acad Dermatol. 2017 Sep;77(3):441-447.e6
pubmed: 28711190
Front Cell Infect Microbiol. 2021 Dec 16;11:747663
pubmed: 34976852
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):1963-1975
pubmed: 34077579
Int J Cosmet Sci. 2018 Aug;40(4):377-387
pubmed: 29879297
Br J Dermatol. 1993 Jun;128(6):650-9
pubmed: 8338749
J Am Acad Dermatol. 2020 Jun;82(6):1501-1510
pubmed: 32035944
J Eur Acad Dermatol Venereol. 2020 Jul;34 Suppl 4:4-25
pubmed: 32677068
J Invest Dermatol. 2011 Mar;131(3):688-97
pubmed: 21107351
Exp Dermatol. 2017 Aug;26(8):659-667
pubmed: 27376863
Maedica (Bucur). 2020 Sep;15(3):416-417
pubmed: 33312262
Mediators Inflamm. 2010;2010:437246
pubmed: 20847936
Dermatol Ther. 2021 Mar;34(2):e14848
pubmed: 33533563
J Mol Med (Berl). 1995 Jan;73(1):7-17
pubmed: 7633944

Auteurs

Enzo Berardesca (E)

Phillip Frost Department of Dermatology, University of Miami, Miami, FL, USA.

Adriana Bonfigli (A)

Clinical Evaluations, ISPE, Milano, Italy.

Claudia Cartigliani (C)

Clinical Evaluations, ISPE, Milano, Italy.

Delphine Kerob (D)

International Scientific Affairs, Cosmetic Active International, Levallois-Perret, France.

Jerry Tan (J)

Department of Medicine and Windsor Clinical Research Inc Western University, Windsor, ON, Canada.

Classifications MeSH